Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Multiple Myeloma Clinical Trial

Official title:

Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03314974
• Other study ID #: 2015LS034
• Secondary ID: MT2015-29
• Status: Recruiting
• Phase: Phase 2
• Start date: March 30, 2018
• Est. completion date: November 10, 2025

Study information

• Verified date: April 2024
• Source: Masonic Cancer Center, University of Minnesota
• Contact: Tamy Grainger
• Phone: (612)-273-2800
• Email: tgraing1[@]fairview.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: November 10, 2025
• Est. primary completion date: January 10, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 60 Years

Eligibility

-Inclusion Criteria:

• Age: = 60 years of age

• Performance Status: Karnofsky = 70%, Lansky play score = 70

• Consent: Voluntary written consent (adult or legally authorized representative; or parental/guardian)

• Adequate Organ Function:

• Renal: Creatinine <2x upper limit of normal. Patients above this limit must have creatinine clearance = 40 ml/min/1.73m2 as determined by an age-appropriate method, such as cystatin C GFR.

• Hepatic: Bilirubin, AST, alkaline phosphatase <4 times the upper limit of institutional normal

• Pulmonary: Diffusion capacity of oxygen, corrected for hemoglobin, > 50% of predicted. For pediatric patients not able to undergo PFTs or diffusion testing: O2 sat of >95% on room air

• Cardiac: Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction > 45%. For children not able to cooperate with MUGA or echocardiography, such should be clearly stated in the physician's documentation

• HIV Status: HIV infection with undetectable viral load. All HIV+ patients must be evaluated by Infectious Disease (ID) and a HIV management plan establish prior to transplantation

Other Inclusion Criteria:

• Women of child bearing potential and sexually active males with partners of child bearing potential must agree to use adequate birth control for the duration of treatment.

• Donor Availability: Patients considered for transplantation must have a sufficient graft as based on current criteria of the University of Minnesota Blood and Marrow Transplantation Program

• Eligible Diseases and Status: Patients are eligible unless their treatment is to be guided by a higher priority protocol.

• Acute Leukemias: Must be in remission by morphology (=5% blasts). Also a small percentage of blasts that is equivocal between marrow regeneration vs. early relapse are acceptable provided there are no associated cytogenetic markers consistent with relapse.

• Acute Myeloid Leukemia (AML) and related precursor neoplasms: 2nd or greater complete remission (CR); first complete remission (CR1) in patients > 60 years old; CR1 in = 60 years old that is NOT considered as favorable-risk.

• Favorable risk AML is defined as having one of the following:

• t(8,21) without cKIT mutation

• inv(16) or t(16;16) without cKIT mutation

• Normal karyotype with mutated NPM1 and wild type FLT-ITD

• Normal karyotype with double mutated CEBPA

• Acute prolymphocytic leukemia (APL) in first molecular remission at the end of consolidation

• Very high risk pediatric patients with AML: Patients <21 years, however, are eligible with (M2 marrow) with < 25% blasts in marrow after having failed one or more cycles of chemotherapy.

• Acute lymphoblastic leukemia (ALL)/lymphoma: second or greater CR; CR1 unable to tolerate consolidation chemotherapy due to chemotherapy-related toxicities; CR1 high-risk ALL.

• High risk ALL is defined as having one of the following:

• Evidence of high risk cytogenetics, e.g. t(9;22), t(1;19), t(4;11), other MLL rearrangements, IKZF1

• 30 years of age or older at diagnosis

• White blood cell counts of greater than 30,000/mcL (B-ALL) or greater than 100,000/mcL (T-ALL) at diagnosis

• CNS leukemia involvement during the course of disease

• Slow cytologic response (>10% lymphoblasts in bone marrow on Day 14 of induction therapy)

• Evidence of persistent immonophenotypic or molecular minimal residual disease (MRD) at the end of induction and consolidation therapy

• Very high risk pediatric patients with ALL: patients <21 years are also considered high risk CR1 if they had M2 or M3 marrow at day 42 from the initiation of induction or M3 marrow at the end of induction. They are eligible once they achieve a complete remission.

• Chronic Myelogenous Leukemia excluding refractory blast crisis: To be eligible in first chronic phase (CP1) patient must have failed or be intolerant to one or more tyrosine kinase inhibitors.

• Plasma Cell Leukemia after initial therapy, in patients who have achieved at least a partial remission

• Myeloproliferative Neoplasms/Myelofibrosis, either primary as a result of polycythemia vera or essential thrombocythemia, with disease risk of intermediate or high-risk according to DIPSS criteria. Blasts must be <10% by bone marrow aspirate morphology.

• Myelodysplasia (MDS) IPSS INT-2 or High Risk (i.e. RAEB, RAEBt) or Refractory Anemia with severe pancytopenia, transfusion dependence, or high risk cytogenetics or molecular features. Blasts must be < 10% by a representative bone marrow aspirate morphology.

• Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Marginal Zone B-Cell Lymphoma or Follicular Lymphoma are eligible if there was disease progression/relapse within 12 of achieving a partial or complete remission. Patients who had remissions lasting > 12 months, are eligible after at least two prior therapies. Patients with bulky disease (nodal mass greater than 5 cm) should be considered for debulking chemotherapy before transplant.

• Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia are eligible after initial therapy in CR1+ or PR1+.

• Diffuse large Cell NHL > CR/> PR: Patients in CR/PR with initial short remission (<6 months) are eligible, or those who have failed/or are not eligible for autologous transplant.

• Lymphoblastic Lymphoma, Burkitt's Lymphoma, and other high-grade NHL after initial therapy if stage III/IV in CR1/PR1 or after progression if stage I/II < 1 year.

• Multiple Myeloma beyond PR2: Patients with chromosome 13 abnormalities, first response lasting less than 6 months, or ß-2 microglobulin > 3 mg/L, may be considered for this protocol after initial therapy.

• Juvenile myelomonocytic leukemia

• Biphenotypic/Undifferentiated/Prolymphocytic Leukemias in first or subsequent CR.

• MRD positive leukemia (AML, ALL or accelerated/blast phase CML). Selected patients in morphologic CR, but with positive immunophenotypic (flow cytometry) or molecular evidence of MRD may be eligible if recent chemotherapy has not resulted in MRD negative status.

• Natural Killer Cell Malignancies

• Acquired Bone Marrow Failure Syndromes except for Fanconi Anemia or Dyskeratosis Congenita

• Other Leukemia Subtypes: A major effort in the field of hematology is to identify patients who are of high risk for treatment failure so that patients can be appropriately stratified to either more (or less) intensive therapy. This effort is continually ongoing and retrospective studies identify new disease features or characteristics that are associated with treatment outcomes. Therefore, if new features are identified after the writing of this protocol, patients can be enrolled with the approval of two members of the study committee.

Exclusion Criteria:

• Chemotherapy refractory large cell and high grade NHL (i.e., progressive disease after > 2 salvage regimens)

• CML in blast crisis

• Large cell lymphoma, mantle cell lymphoma and Hodgkin disease that is progressing on salvage therapy.

• Evidence of progressive disease by imaging modalities or biopsy - persistent PET activity, though possibly related to lymphoma, is not an exclusion criterion in the absence of CT changes indicating progression.

• Active central nervous system malignancy

• if = 18 years old, prior myeloablative transplant within the last 6 months. If >18 years old prior myeloablative allotransplant or autologous transplant

• Active HIV infection or known HIV positive serology

• active uncontrolled infection

• Pregnant or breastfeeding. The agents used in this study include Pregnancy Category D:

known to cause harm to a fetus. Females of childbearing potential must have a negative pregnancy test prior to starting therapy.

Related Conditions & MeSH terms

• Acquired Bone Marrow Failure Syndromes
• Acute Leukemia
• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Anemia
• Biphenotypic/Undifferentiated/Prolymphocytic Leukemias
• Bone Marrow Failure Disorders
• Burkitt Lymphoma
• Chronic Lymphocytic Leukemia
• Chronic Myelogenous Leukemia
• Diffuse Large Cell Non Hodgkins Lymphoma
• Follicular Lymphoma
• High Grade Non-Hodgkin's Lymphoma, Adult
• High Risk Anemia
• Juvenile Myelomonocytic Leukemia
• Leukemia
• Leukemia, Lymphocytic, Chronic, B-Cell
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid
• Leukemia, Myelomonocytic, Juvenile
• Leukemia, Plasma Cell
• Leukemia, Prolymphocytic
• Lymphoblastic Lymphoma
• Lymphoma
• Lymphoma, B-Cell, Marginal Zone
• Lymphoma, Mantle-Cell
• Lymphoma, Non-Hodgkin
• Lymphoplasmacytic Lymphoma
• Mantle-Cell Lymphoma
• Marginal Zone B-Cell Lymphoma
• MRD Positive Leukemia
• Multiple Myeloma
• Myelodysplasia
• Myelofibrosis
• Myeloproliferative Disorders
• Myeloproliferative Neoplasms
• Natural Killer Cell Malignancies
• Pancytopenia
• Plasma Cell Leukemia
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Prolymphocytic Leukemia
• Refractory Anemia
• Small Lymphocytic Lymphoma
• Waldenstrom Macroglobulinemia

Intervention

Biological:
• HSCT with TBI Regimen
Day -5 to -2: Total Body Irradiation Day 0: Hematopoietic Stem Cell Transplantation Day +3 to +4: Cyclophosphamide Day +5: Tacrolimus from day +5 until taper day +100 (day +60 for peds if no acute or chronic GVHD present) Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD
• HSCT with Non-TBI Regimen
Day -5 to Day -2: Busulfan and Fludaribine Day 0: Hematopoietic Stem Cell Transplantation Day +3 to +4: Cyclophosphamide Day +5: Tacrolimus from day +5 until taper day +100 (day +60 for peds if no acute or chronic GVHD present) Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD

Locations

Country	Name	City	State
United States	Masonic Cancer Center at University of Minnesota	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Masonic Cancer Center, University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Chronic GVHD - 1 year	Incidence of chronic GVHD	1 year
Secondary	Grade II-IV acute GVHD	Cumulative incidence grade II-IV acute GVHD	Day +100
Secondary	Chronic GVHD - 2 years	Incidence of chronic GVHD	2 years
Secondary	Relapse	Cumulative incidence of relapse	2 years
Secondary	Overall survival	Cumulative incidence of overall survival	2 years
Secondary	Treatment-related mortality	Cumulative incidence of treatment-related mortality	2 years
Secondary	Graft-versus-host disease-free, relapse free survival (GRFS)	Cumulative incidence of GRFS	1 year
Secondary	Graft-versus-host disease-free, relapse free survival (GRFS)	Cumulative incidence of GRFS	2 years
Secondary	Neutrophil Engraftment	Cumulative incidence of Neutrophil Engraftment	Day 42
Secondary	Neutrophil Engraftment	Cumulative incidence of Neutrophil Engraftment	6 months
Secondary	Platelet Engraftment	Cumulative incidence of Platelet Engraftment	Day 42
Secondary	Platelet Engraftment	Cumulative incidence of Platelet Engraftment	6 months